HC Wainwright Estimates Editas Medicine Q1 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of Editas Medicine in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright currently has a "Strong-Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Editas Medicine's Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.50) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($1.49) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm had revenue of $30.60 million for the quarter, compared to analyst estimates of $37.17 million. During the same period in the prior year, the firm posted ($0.23) earnings per share.

Separately, Cantor Fitzgerald raised Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $6.54.

Editas Medicine Price Performance

Shares of NASDAQ EDIT traded down $0.15 on Thursday, hitting $1.40. The company's stock had a trading volume of 999,218 shares, compared to its average volume of 2,570,516. The stock has a 50 day moving average of $1.41 and a 200-day moving average of $1.75. The company has a market capitalization of $116.78 million, a price-to-earnings ratio of -0.54 and a beta of 2.14. Editas Medicine has a 12-month low of $0.91 and a 12-month high of $6.69.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ieq Capital LLC purchased a new stake in Editas Medicine during the 4th quarter worth $31,000. Thrive Wealth Management LLC acquired a new stake in Editas Medicine during the 4th quarter valued at approximately $36,000. Dark Forest Capital Management LP increased its holdings in Editas Medicine by 66.9% during the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock worth $42,000 after purchasing an additional 13,138 shares during the last quarter. Brave Asset Management Inc. boosted its stake in Editas Medicine by 250.0% during the 1st quarter. Brave Asset Management Inc. now owns 35,000 shares of the company's stock valued at $41,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Editas Medicine by 45.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 35,781 shares of the company's stock worth $40,000 after acquiring an additional 11,252 shares in the last quarter. 71.90% of the stock is owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.